Moderna and Merck announced Wednesday that their personalized mRNA cancer vaccine met its main goals in a Phase 3 trial targeting melanoma. The trial included 1,137 patients with high-risk melanoma who had their tumors surgically removed. Patients who received the vaccine alongside Merck’s Keytruda went longer without their cancer coming back or spreading than those who received Keytruda alone. This marks the first time a therapy of this kind has succeeded at the Phase 3 stage. Moderna shares more than doubled on the news, while Merck shares also climbed. The companies plan to share full data at an upcoming medical conference and bring the results to regulators.
Source: Read the original article
